Research Article

Dr. Answer AI for prostate cancer: Intention to use, expected effects, performance, and concerns of urologists

Mi Jung Rho a,1, Jihwan Park b,1, Hyong Woo Moon c, Choung-Soo Kim d, Seong Soo Jeon e, Minyong Kang f, Ji Youl Lee c,∗

a College of Health Science, Dankook University, Cheonan-si, Korea
b School of Software Convergence, College of Software Convergence, Dankook University, Korea
c Department of Urology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
d Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
e Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
f Department of Urology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

ARTICLE INFO

Article history:
Received 14 March 2021
Received in revised form 3 September 2021
Accepted 30 September 2021
Available online 23 November 2021

Keywords:
Artificial intelligence
Acceptance
Doctor’s Answer
Prostate cancer
PROMISE CLIP project

ABSTRACT

Objectives: To efficiently implement artificial intelligence (AI) software for medical applications, it is crucial to understand the acceptance, expected effects, expected performance, and concerns of software users. In this study, we examine the acceptance and expectation of the Dr. Answer AI software for prostate cancer.

Methods: We conducted an online survey for urologists from August 13 to September 18, 2020. The target software is an AI-based clinical software called Dr. Answer AI software, used for prostate cancer diagnosis. We collected data from 86 urologists and conducted a basic statistical and multiple regression analysis using the R package.

Results: The compatibility was significantly associated with the intention to use the Dr. Answer AI software. The expected average accuracy for the software ranges from 86.91% to 87.51%, and the urologists perceived that the cloud method is suitable to introduce the software. The most desirable function of the software for the specialists is predicting the occurrence of extracapsular extension, seminal vesicle invasion, and lymph node metastasis after radical prostatectomy. Finally, the primary concerns involved the cost, compatibility with existing systems, and obtaining accurate information from the software.

Conclusions: Our results present an understanding of the acceptance, expected effects, expected performance, and concerns of software users. The results provide a guide to help AI software be properly developed and implemented in medical applications.

© 2022 Asian Pacific Prostate Society. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

In recent times, the field of medical artificial intelligence (AI) has advanced significantly with the development of new technology. AI model development and services are being utilized for diagnosis, treatment, and outcome prediction in urologic diseases.1–4

In Korea, the largest AI software (SW) project called Dr. Answer began in 2018, led by the National IT Industry Promotion Agency.5,6 The Dr. Answer AI project has 26 participating universities, associate general and general hospitals, and 22 companies focusing on eight diseases, including cardio-cerebral vascular disease, heart disease, breast cancer, colon cancer, prostate cancer (PCA), dementia, epilepsy, and incurable childhood genetic diseases.7 The Dr. Answer project aims to secure AI learning medical data for AI SW development to improve the diagnosis and treatment of major diseases.

Currently, the most important issue in the field of medical AI in South Korea is the licensing and commercialization of AI SW. Efficient utilization of such AI SW in medical applications is of utmost importance. Hence, understanding the acceptance and expected effects of SW users needs to be considered.

PCA is a common cancer that mainly occurs in the elderly,8 one of the leading causes of death in men in the world.9,10 Efforts are being made to overcome it by applying AI technology. The Dr. Answer AI project has developed various AI-based SWs. Here, we examine the acceptance, expected effects, expected performance, and concerns of the Dr. Answer SW AI for PCA.
2. Material and methods

2.1. Respondents: urologists

We conducted an online survey for urologists from August 13 to September 18, 2020. The survey was conducted with 1,100 members of the Korean prostate society (http://www.theprostate.org). All participants completed an anonymous survey. We sent the questionnaire via e-mail twice during the survey period. Before the survey, an explanation of the Dr. Answer AI SW was presented to the respondents, including descriptive images and videos. The participant data were de-identified during analysis.

2.2. Dr. Answer AI SW for PCa

Among the 26 participating hospitals in the Dr. Answer AI project, we focused on the PROstate Medical Intelligence System Enterprise-Clinical, Imaging, and Pathology (PROMISE CLIP) project. The PROMISE CLIP project has four hospitals: Seoul St. Mary’s Hospital of the Catholic University, Seoul National University Bundang Hospital, Samsung Medical Center, and Asan Medical Center. There are three SW used for PCa diagnosis: SWs for clinical, pathology, and imaging.

Among three SWs, we focused on clinical SW. LifeSemantics Corp. developed the clinical SW for PCa (Fig. 1), which is a company in the digital health platform business using AI. The clinical SW screen is largely divided into a patient information section and a clinical outcome prediction section. In patient information, there are patient information and lab data such as Atypical Small Acinar Proliferation, biopsy score, bone scan, CT, Gleason score, MRI images, PIN, PSA, and TNM (tumor, node, and metastasis). The SW shows the change over time of the PSA in graph format. In the clinical outcome prediction function, the SW provides clinical outcome such as prediction probability of occurrence in TNM staging, extracapsular extension, seminal vesicle invasion, lymph node metastasis, and predicting biochemical recurrence (BCR) after radical prostatectomy (RP). The clinical SW could help patients with PCa and physicians make treatment decisions.

2.3. Factors definition

Based on existing literature, we used a total of five factors. Intention to use refers to the degree to which a physician’s behavioral intention tends to use the Dr. Answer AI SW. The intention to use is scored with a five-point Likert scale rated as: (1) strongly disagree, (2) disagree, (3) neither agree nor disagree, (4) agree, and (5) strongly agree. There are four questions (Supplementary Table 1).

The four independent variables are as follows: perceived usefulness, responsibility, reimbursement, and compatibility. The perceived usefulness is defined as the finding predictor of technology in the healthcare industry. We modified the definition of the originally perceived usefulness based on the TAM model. In this study, the perceived usefulness refers to the degree to which a urologist believes that the use of AI SW would improve his or her cancer treatment outcomes and processes. There are five questions.

Responsibility refers to the degree to which potential adopters are aware of the risks and liabilities for problems that may arise from the use of AI SW. To implement new technologies in medical applications, assuming responsibility for problems is a crucial issue. In the case of public health care aids such as telemedicine, the government may take responsibility for such services. AI SW can be implemented suitably when medical professionals have a clear responsibility for using the SW, and there is no burden associated with it. There are four questions.

For implementing new technologies sustainably in medical applications, the cost effectiveness of usage must be considered. Previous studies have explored the introduction and usage of technology in medical applications. In this study, reimbursement refers to the degree to which a physician believes using the Dr. Answer AI SW will be rewarded by financial support or compensation. There are four questions.

Compatibility refers to the degree to which a technology is perceived by potential adopters as consistent with their current values, previous experience, and needs. Compatibility positively influences the acceptance of AI technology in the healthcare industry. Wu et al. demonstrated that compatibility has a positive relationship with the perceived usefulness, ease of use, and usage.

Fig. 1. Dr. Answer AI SW for PCa.
intention in mobile computing acceptance. There are four questions. All questionnaires were scored with a five-point Likert scale.

2.4. Statistical analysis

We conducted a basic statistical and multiple regression analysis using the R program (version 4.3.5.0). We used the “enter” method for inputting independent variables as the variable selection method.

2.5. Ethical statement

The study was performed in accordance with the Declaration of Helsinki and was approved by three Institutional Review Boards: Catholic University (IRB number: KC20RISI0400).

3. Results

3.1. Participant characteristics

A total of 86 urologists out of the 1,100 members of the Korean prostate society participated. The response rate was 7.82% (Table 1). Since there were no missing values, all response data were used for analysis. In the case of urology, there are submajors such as children, urination, and tumors, but submajors were not classified.

Table 1

| Variables                | Frequency | Percent |
|--------------------------|-----------|---------|
| Gender                   |           |         |
| Male                     | 80        | 93.0    |
| Female                   | 6         | 7.0     |
| Age                      |           |         |
| 20–29 years              | 1         | 1.2     |
| 30–39 years              | 19        | 22.1    |
| 40–49 years              | 44        | 51.2    |
| Over 50 years            | 22        | 25.6    |
| Position                 |           |         |
| Intern                   | 2         | 2.3     |
| Clinical fellow          | 3         | 3.5     |
| Pay doctor               | 12        | 14.0    |
| Professor                | 51        | 59.3    |
| Opening doctor           | 18        | 20.9    |
| Career                   |           |         |
| Under 10 years           | 11        | 12.8    |
| 11–20 years              | 49        | 57.0    |
| 21–30 years              | 22        | 25.6    |
| Over 31 years            | 4         | 4.7     |
| Hospital type            |           |         |
| Private hospital         | 19        | 22.1    |
| Associate general hospital* | 2          | 2.3   |
| University hospital      | 57        | 66.3    |
| General hospital         | 8         | 9.3     |
| Hospital location        |           |         |
| Seoul                    | 23        | 26.7    |
| Busan                    | 7         | 8.1     |
| Daegu                    | 5         | 5.8     |
| Incheon                  | 3         | 3.5     |
| Gwangju                  | 5         | 5.8     |
| Ulsan                    | 2         | 2.3     |
| Gyeonggi-do province     | 17        | 19.8    |
| Chungcheongbuk-do province | 3       | 3.5 |
| Jeollabuk-do province    | 1         | 1.2     |
| Jeollanam-do province    | 4         | 4.7     |
| Gyeongsangbuk-do province | 3         | 3.5     |
| Gyeongsangnam-do province | 2       | 2.3     |
| Cheju                    | 3         | 3.5     |
| No response              | 8         | 9.3     |
| Experience               |           |         |
| with CDSS                |           |         |
| Yes                      | 10        | 11.6    |
| No                       | 76        | 88.4    |
| Total                    | 86        | 100.0   |

*Associate general hospital: hospital with several medical offices, smaller than a general hospital. CDSS, clinical decision support system.

Further, 46.5% worked in Seoul and Gyeonggi-do, and 11.6% had experience in using the clinical decision support systems.

3.2. Factor influencing the intention to use Dr. Answer AI SW

Before multiple regression analysis, five variables were evaluated on the internal consistency reliability using Cronbach’s alpha (Supplementary Table 2).

The values for all constructs ranged between 0.677 and 0.863 (0.816 for intention, 0.863 for responsibility, 0.784 for compatibility, 0.78 for reimbursement, and 0.677 for perceived usefulness). The values for the three constructs were >0.7. Consequently, Cronbach’s alpha for all constructs was reliable.

We performed a principal component analysis with varimax rotation to test the construct validity. The cross-loadings were lower than the corresponding factor loadings. Five factors emerged with no-cross construct loadings above 0.50. The analysis also demonstrated convergent validity with factor loadings exceeding 0.50 for each construct. The results confirmed the existence of four factors with eigenvalues >1.0, which accounted for 71.94% of the total variance. The communality ranged between 0.529 and 0.817, with all items achieving 0.50 (Supplementary Table 2). These results confirm that the four constructs were distinct unidimensional scales. We used four valid constructs: four items for intention, three items for responsibility, three items for compatibility, three items for reimbursement, and three items for perceived usefulness (Supplementary Table 2).

We derived the factors using multiple regression analysis (Table 2). The compatibility (t = 5.564) was significantly associated with only the intention to use the Dr. Answer AI SW (F = 12.000). The coefficient of determination (R²) for this model was 0.372, indicating that 37.2% of the variation in the intention to use the Dr. Answer AI SW can be attributed to a single independent variable.

3.3. Expected accuracy for the Dr. Answer AI SW and SW introduction method

The questionnaire included questions about the expected accuracy of the Dr. Answer AI SW. The questionnaire of expected accuracy is self-written, and the range of the input value is specified as 50%–100%. The expected accuracy is 86.91% in predicting the occurrence of extracapsular extension, seminal vesicle invasion, and lymph node metastasis after radical prostatectomy. The expected accuracy is 87.51% in predicting TNM staging. In addition, the expected accuracy was 86.76% in predicting BCR after RP (see Table 3).

The following presents the results on the introduction of the Dr. Answer AI SW: 58.1% of respondents said that the cloud method is suitable. However, 86.4% of the respondents answered that, in the case of the stand-alone method, the linkage method with the existing system is suitable as the introduction method (see Table 4).

3.4. Expected effect of the Dr. Answer AI SW

After setting the state before SW development to 100, a questionnaire was developed to record the expected effect on this basis. The diagnostic accuracy was expected to improve by 79.3% on average. The treatment outcome was expected to improve by 78.84% on average. After treatment, the outcome explanatory time was expected to decrease by 26.28% on average. The outpatient time is expected to decrease by 34.07% on average. The respondents expected a 36.05% reduction in working hours on average (see Table 5).
3.5. Expected function of the Dr. Answer AI SW

We asked the respondents to rank the functions to be incorporated in the Dr. Answer AI SW. Most urologists responded that it is necessary to predict the occurrence of extracapsular extension, seminal vesicle invasion, and lymph node metastasis after surgery with the Dr. Answer SW. This was followed by TNM staging prediction, death prediction, BCR prediction, quality of life, and time-series data in order (see Fig. 2).

Other responses include active surveillance, functional outcome after RP (urinary incontinence rate, sexual dysfunction, urination disorder, etc.), survival rate, prognosis prediction without RP, survival time prediction without radical prostatectomy, remote metastasis prediction, post-treatment symptom prediction, treatment pain prediction, recurrence rate, and complications in treatment.

3.6. Concerns about introduction of Dr. Answer AI SW

Urologists were concerned about the cost of using SW and its compatibility with existing systems. There were high concerns about whether they could properly receive the desired information. In addition, urologists were concerned about the extent to which the Dr. Answer AI SW would aid in diagnosis (see Fig. 3).

4. Discussion

We examined the acceptance, expected effects, expected performance, and concerns of urologists in using the Dr. Answer AI SW for PCa.

First, compatibility is the most important factor in introducing the Dr. Answer AI SW. Compatibility is also a concern for SW acceptance. Compatibility may or may not be an influencing factor depending on potential users, technologies, and fields of introduction. Previous studies have determined that compatibility has a positive relationship with the intention to use, although some studies did not.23

Urologists preferred that the introduction of AI SW should be compatible with their current methods. It is important to develop AI SW that is fully compatible with current systems and treatment methods. Urologists preferred the cloud method of introducing SW (58.1%). In addition, in the case of the stand-alone method, compatibility with existing systems is considered important (86.4%). Therefore, it should be considered whether it will be well reflected in the introduction environment and treatment process from the beginning of SW development.

Second, the average expected accuracy for the SW ranged from 86.91% to 87.51%. The expected accuracy of predicting the occurrence of extracapsular extension, seminal vesicle invasion, and lymph node metastasis after radical prostatectomy is 86.91%. The expected accuracy is 87.51% in the case of predicting TNM staging. In addition, the expected accuracy is 86.76% in case of BCR after RP. When developing medical SW algorithms, there are no guidelines for reference accuracy. Moreover, expectations for accuracy vary depending on the disease and the intended use of the SW. The expected accuracy determined in this study can be used as a reference when developing a similar SW.

Third, the diagnostic accuracy was expected to improve by 79.3%, and the treatment outcome was expected to improve by...
Fig. 2. Derived functions of the SW.

Fig. 3. Concerns about introduction of Dr. Answer AI SW.
78.84%. The effect that urologists expected was higher than our estimate. In addition, after treatment, the outcome explanatory time was expected to decrease by 26.28%. The outpatient time is expected to decrease by 34.07%. Respondents expected a 36.05% reduction in working hours. Long waiting time and appropriate outpatient time have been previously discussed and reported to increase patient satisfaction.\textsuperscript{24,25} However, reducing the outpatient time is difficult in healthcare. Depending on the characteristics, each department has a different treatment time to satisfy patients.\textsuperscript{26} Saving time by 26%–36% is a significant result. According to Kim et al., the average outpatient cost for Korean patients after RP was reported at $161 per year.\textsuperscript{27} Based on this result, the economic value of the reduced outpatient time can be calculated. If the outpatient time can be reduced by 34.07%, it can be effective at saving $54.74 per patient per year. As the outpatient time is reduced, the idle time can be increased for urologists, and they can potentially attend to more PCa patients. Thus, the patient waiting time can also be reduced. The cost reduction effect can also be used for medical cost analysis. According to Bennett and Hauser (2013), it is reported that more than 50% of improvement can be achieved at half the cost through AI algorithms.\textsuperscript{28} We hope that research on the effectiveness and cost reduction effect of AI will continue in the future.

However, it should be considered that there are many people who responded with 0% in the expected effect response. There is a need to develop SW that can alleviate these concerns of urologists. Various SW for PCa are being developed and commercialized, and these low expectations can also be expected to change.

Fourth, most urologists responded that the occurrence of extracapsular extension, seminal vesicle invasion, and lymph node metastasis should be predicted after surgery with the Dr. Answer SW function. Thereafter, TNM staging prediction, death prediction, BCR prediction, quality of life, and time-series data become in order. In the case of PCa, the mortality rate is low;\textsuperscript{29} thus, it is difficult to obtain data to develop a model that predicts mortality, which was not incorporated in the Dr. Answer AI SW for PCa. There are other SW features that urologists expect, such as active surveillance, functional outcome after RP (urinary incontinence rate, sexual dysfunction, incontinence disorder, etc.), survival rate, prognosis prediction without RP, survival time prediction without radical prostatectomy, remote metastasis prediction, post-treatment symptom prediction, treatment pain prediction, and recurrence rate and complications in treatment. These functions need to be investigated and developed in the future.

Finally, urologists were concerned about the cost of using the SW. There were significant concerns about whether they could properly receive the desired information. Urologists were concerned to what extent the Dr. Answer AI SW would aid in patient diagnosis. The cost effectiveness in the commercialization of AI SW remains to be solved. In the case of government and hospital-led projects, the results will be different. In addition, concerns about accurate information and usefulness are expected to be overcome through further developments and applications.

There are some limitations. First, we used data from 86 Korean urologists. Owing to the sample size, the interpretation of the analysis is limited. The results will be more generalizable if more responses are included. Second, the target SW is a clinical SW for PCa. In the case of PCa, the expected effect or accuracy may be different for pathology and imaging. Further research should be conducted according to specific SW targets and potential users for better results. Third, the expected effect was viewed based on the average value, but it can be evaluated differently in terms of the mode or median. Therefore, the explanation and interpretation of the results should be considered. Fourth, this study was conducted with urologists who have not used the Dr. Answer AI SW. In addition, only 11.6% of respondents have CDSS experience. There may be limitations in our results.

We present guidelines on the acceptance, expected effects, expected performance, and concerns of urologists in using AI SW. This study could help develop and introduce AI software that better reflects the medical environment.

Conflicts of interest

Mi Jung Rho and Jihwan Park are married couples and are co-participating in the project. For the rest of the authors, there are no conflicts of interest to declare.

Acknowledgment

This study was supported by Institute for Information & Communications Technology Promotion (IITP) grant funded by the Korea government (MSIT) (2018-0-00861, Intelligent SW Technology Development for Medical Data Analysis). We are grateful to the members of the Korean Prostate Society for cooperating with the online survey.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.prnil.2021.09.001.

References

1. Tsao C-W, Liu C-Y, Cha T-L, Wu S-T, Sun G-H, Yu D-S, et al. Artificial neural network for predicting pathological stage of clinically localized prostate cancer in a Taiwanese population. J Chin Med Assoc 2014;77:513–8.
2. Cosma G, Acampora G, Brown D, Rees RC, Khan M, Pockley AG. Prediction of pathological stage in patients with prostate cancer: a neuro-fuzzy model. PLoS One 2016;11:e0155856.
3. Bakken S, Grullon-Figueroa L, Izquierdo R, Lee N-J, Morin P, Palmas W, et al. Development, validation, and use of English and Spanish versions of the telemedicine satisfaction and usefulness questionnaire. J Am Med Inf Assoc 2006;13:660–7.
4. van Booven DJ, Kuchakulla M, Pai R, Frech FS, Ramasahayam R, Reddy P, et al. A Systematic Review of Artificial Intelligence in Prostate Cancer. Res Rep Urol 2021;13:31.
5. Consortium KDAs-dh. Dr. Answer; 2018 [2020.10]. Available from: http://dranswer.kr/.
6. Park S, Jho M, Park YH, Jung CK, Chong Y, Kim CS, et al. Promise clip project: A retrospective, multicenter study for prostate cancer that integrates clinical, imaging and pathology data. Appl Sci 2019;9:2986.
7. Rho MJ, Park J, Moon HW, Lee C, Nam S, Kim D, et al. Dr. Answer AI for prostate cancer: Clinical outcome prediction model and service. Plos One 2020;15:e0236553.
8. Gurjar OP, Arya R, Goyal H. A study on prostate movement and dosimetric variation because of bladder and rectum volumes changes during the course of image-guided radiotherapy in prostate cancer. Prostate Int 2020;8:91–7.
9. Yuri P, Shigemura K, Kitagawa K, Hidabrata E, Risan M, Zulfikhar A, et al. Increased tumor-associated macrophages in the prostate cancer microenvironment predicted patients’ survival and responses to androgen deprivation therapies in Indonesian patients cohort. Prostate Int 2020;8:62–9.
10. Celik S, Eker A, Bozkurt IH, Bolat D, Basmaci I, Sefik E, et al. Factors affecting biochemical recurrence of prostate cancer after radical prostatectomy in patients with positive and negative surgical margin. Prostate Int 2020;8:178–84.
11. Park S, Kim JY, Lee JC, Kim HR, Song S, Kwon H, et al. Mobile phone app—based pulmonary rehabilitation for chemotherapy-treated patients with advanced lung cancer: pilot study. JMIR mHealth uHealth 2019;7:e11094.
12. Kwon H, Nam K-W, Lee Y, Kwon H-M, Chung YS. Remote management of poststroke patients with a smartphone-based management system integrated in clinical care: prospective, nonrandomized, interventional study. J Med Internet Res 2020;22:e15377.
13. Venkatesh V, Morris MG, Davis GB, Davis FD. User acceptance of information technology: Toward a unified view. MIS Q 2003:425–78.
14. Schaper UK, Pervan GP, ICT and OTs: A model of information and communication technology acceptance and utilisation by occupational therapists. Int J Med Inf 2007;76:S212–21.
15. Rho MJ, Kim HS, Chung K, Choi IY. Factors influencing the acceptance of telemedicine for diabetes management. Cluster Comput 2015;18:321–31.
16. Davis FD. Perceived usefulness, perceived ease of use, and user acceptance of information technology. MIS Q 1989:319–40.
17. Rho MJ, young Choi I, Lee J. Predictive factors of telemedicine service acceptance and behavioral intention of physicians. Int J Med Inf 2014;83:559–71.
18. Liu C-F. Key factors influencing the intention of telecare adoption: An institutional perspective. Telemed e-Health 2011;17:288–93.
19. Olver IN, Selva-Nayagam S. Evaluation of a telemedicine link between Darwin and Adelaide to facilitate cancer management. Telemed J 2000;6:213–8.
20. Rogers EM. Diffusion of innovations. Simon & Schuster; 2010.
21. Wu J-H, Wang S-C, Lin L-M. Mobile computing acceptance factors in the healthcare industry: A structural equation model. Int J Med Inf 2007;76:66–77.
22. Nunnally JC. Psychometric theory 3E. Tata McGraw-hill education; 1994.
23. Chau PY, Hu PJ. Examining a model of information technology acceptance by individual professionals: An exploratory study. J Manag Inf Syst 2002;18:191–229.
24. Sun J, Lin Q, Zhao P, Zhang Q, Xu K, Chen H, et al. Reducing waiting time and raising outpatient satisfaction in a Chinese public tertiary general hospital-an interrupted time series study. BMC Public Health 2017;17:668.
25. Almomani I, Alsarheed A. Enhancing outpatient clinics management software by reducing patients’ waiting time. J Infect Public Health 2016;9:734–43.
26. Lee CH, Lim H, Kim Y, Park AH, Park E-C, Kang J-G. Analysis of appropriate outpatient consultation time for clinical departments. Health Pol Manag 2014;24:254–60.
27. Kim JM, Rho MJ, Jang KS, Park YH, Lee JY, Choi IY. Cost Comparison of Androgen Deprivation Therapy and Radical Prostatectomy for Prostate Cancer. Korea J Hosp Manag 2018;23:28–38.
28. Bennett CC, Hauser K. Artificial intelligence framework for simulating clinical decision-making: A Markov decision process approach. Artif Intell Med 2013;57:9–19.
29. Park J, Rho MJ, Moon HW, Park YH, Kim C-S, Jeon SS, et al. Prostate cancer trajectory-map: clinical decision support system for prognosis management of radical prostatectomy. Prostate Int 2021;9:25–30.